Effects of exenatide on glycemic control over 52 weeks in patients with type 2 diabetes

Chinese Pharmaceutical Journal

Volumn 49, Issue 11, 2014, Pages 941-943

  Su, Xian ^a   Zhao, Ting Qi ^b  

^a PEKING UNIVERSITY   (China)

^b NINGBO UNIVERSITY   (China)

Author keywords

Exenatide; Insulin glargine; Type 2 diabetes mellitus

Indexed keywords

EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; METFORMIN;

ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; DIABETIC PATIENT; DRUG EFFECT; DRUG SAFETY; DRUG TREATMENT FAILURE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

EID: 84903724324     PISSN: 10012494     EISSN: None     Source Type: Journal    
DOI: 10.11669/cpj.2014.11.008     Document Type: Article

References (4)

1. BUSE J B, BERGENSTAL R M, GLASS L C, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: A randomized, controlled trial[J]. Ann Intern Med, 2011, 154(2): 103-112
2. QIAN R L, XIANG K S, CHEN J W, et al. China Diabetes Prevention Guide (2004) [S]. 2004: 72.
3. THONG K Y, JOSE B, SUKUMAR N, et al. ABCD Nationwide exenitide audit contributors safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit[J]. Diabetes Obes Metab, 2011, 13(8): 703-710.
4. GARG S K. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes-a comprehensive review[J]. Diabetes Technol Ther, 2010, 12(1): 11-24.